FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022266143> ?p ?o ?g. }

• W2022266143 endingPage "443" @default.
• W2022266143 startingPage "437" @default.
• W2022266143 abstract "Intratumoral grafting of genetically engineered cells that produce interleukin-4 (IL-4) has been shown to produce tumor regression as well as prolong survival of mice harboring intracerebral gliomas. We sought to determine whether retroviral-mediated gene delivery into tumor cells in situ resulted in enhanced tumor regression by IL-4. Two mouse fibroblast lines were obtained: they both secreted similar levels of IL-4 but one produced a retrovirus vector bearing the IL-4 gene (CRE-MFG-IL-4 cells), whereas the other did not (NIH3T3-IL-4 cells). In mixed transplantation assays in the subcutaneous flanks of athymic mice, CRE-MFG, IL-4 cells were more effective than NIH3T3-IL-4 cells in inhibiting the growth of rat C6 glioma cells (p < 0.005, ANOVA). Subcutaneous tumors injected with fibroblasts that produced a control retrovirus vector without producing IL-4 (CRE-MFG-LacZ cells) did not inhibit subcutaneous tumor growth. An intracranial assay was used to evaluate survival of athymic mice harboring intracranial gliomas. Three days after implanting rat C6 glioma cells into the right frontal lobes of athymic mice, NIH3T3-IL-4 cells (n = 10) or CRE-MFG-IL-4 cells (n = 10) were stereotactically inoculated into the tumor bed. The average survival of mice treated with CRE-MFG-IL-4 cells was 38 days (±2.4, SE), whereas that of mice treated with NIH3T3-IL-4 cells was 31 days (±0.8, SE) (p < 0.005, ANOVA; p < 0.001, log-rank analysis). The mean survival of control mice treated with CRE-MFG-LacZ cells was only 25 days (±0.7, SE) (p < 0.0001, compared to CRE-MFG-IL-4-treated mice). Histologic analysis of animals' tumors revealed extensive eosinophilic infiltrates in mice treated with the IL-4-producing cells (both NIH3T3-IL-4 and CRE-MFG-IL-4) but not in mice treated with IL-4 nonproducing cells (CRE-MFG-LacZ). This infiltrate started to decrease 3 weeks after fibroblast implantation, implying that its maintenance was needed for prolonged tumor regression. This study demonstrates that in situ retroviral-mediated transfer of the IL-4 gene enhances the anticancer effect of cells that produce the cytokine. Interleukin-4 (IL-4) has been shown to produce the regression of experimental brain tumors. This has been achieved by grafting cells genetically engineered to produce this cytokine. We have used a mouse fibroblast cell line that produces not only IL-4 but also a retrovirus vector that bears an IL4 transgene. As a control, we have made a mouse fibroblast cell line that produces the same levels of IL4 but that does not make retrovirus. We show that the IL4-retrovirus producer line is superior to the IL4-producing cells in achieving regression of subcutaneous brain tumors. In an intracerebral glioma model, the former cells produced more significant extensions in animal survival than the latter. These results indicated that the in situ retroviral gene delivery of IL-4 into brain tumors significantly extended the survival of mice compared to the in situ production of IL-4." @default.
• W2022266143 created "2016-06-24" @default.
• W2022266143 creator A5002067050 @default.
• W2022266143 creator A5003952553 @default.
• W2022266143 creator A5026853539 @default.
• W2022266143 creator A5050200813 @default.
• W2022266143 creator A5059033742 @default.
• W2022266143 creator A5079438469 @default.
• W2022266143 date "1995-04-01" @default.
• W2022266143 modified "2023-09-27" @default.
• W2022266143 title "Enhancement of Interleukin-4-Mediated Tumor Regression in Athymic Mice by <i>In Situ</i> Retroviral Gene Transfer" @default.
• W2022266143 cites W1972464496 @default.
• W2022266143 cites W1973317990 @default.
• W2022266143 cites W1974997501 @default.
• W2022266143 cites W1989775015 @default.
• W2022266143 cites W1989860131 @default.
• W2022266143 cites W1991148746 @default.
• W2022266143 cites W1991934910 @default.
• W2022266143 cites W1996953939 @default.
• W2022266143 cites W2005010475 @default.
• W2022266143 cites W2013618157 @default.
• W2022266143 cites W2017122884 @default.
• W2022266143 cites W2026922744 @default.
• W2022266143 cites W2032723037 @default.
• W2022266143 cites W2039571462 @default.
• W2022266143 cites W2046555621 @default.
• W2022266143 cites W2047956692 @default.
• W2022266143 cites W2056022736 @default.
• W2022266143 cites W2062893063 @default.
• W2022266143 cites W2065434365 @default.
• W2022266143 cites W2066908082 @default.
• W2022266143 cites W2067379696 @default.
• W2022266143 cites W2082102301 @default.
• W2022266143 cites W2091691801 @default.
• W2022266143 cites W2091987058 @default.
• W2022266143 cites W2108417705 @default.
• W2022266143 cites W2140098095 @default.
• W2022266143 cites W2171009645 @default.
• W2022266143 cites W2416210793 @default.
• W2022266143 doi "https://doi.org/10.1089/hum.1995.6.4-437" @default.
• W2022266143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7612701" @default.
• W2022266143 hasPublicationYear "1995" @default.
• W2022266143 type Work @default.
• W2022266143 sameAs 2022266143 @default.
• W2022266143 citedByCount "61" @default.
• W2022266143 countsByYear W20222661432013 @default.
• W2022266143 countsByYear W20222661432014 @default.
• W2022266143 countsByYear W20222661432018 @default.
• W2022266143 countsByYear W20222661432020 @default.
• W2022266143 crossrefType "journal-article" @default.
• W2022266143 hasAuthorship W2022266143A5002067050 @default.
• W2022266143 hasAuthorship W2022266143A5003952553 @default.
• W2022266143 hasAuthorship W2022266143A5026853539 @default.
• W2022266143 hasAuthorship W2022266143A5050200813 @default.
• W2022266143 hasAuthorship W2022266143A5059033742 @default.
• W2022266143 hasAuthorship W2022266143A5079438469 @default.
• W2022266143 hasConcept C104317684 @default.
• W2022266143 hasConcept C111599444 @default.
• W2022266143 hasConcept C153911025 @default.
• W2022266143 hasConcept C191732599 @default.
• W2022266143 hasConcept C203014093 @default.
• W2022266143 hasConcept C2522874641 @default.
• W2022266143 hasConcept C2778227246 @default.
• W2022266143 hasConcept C2778431562 @default.
• W2022266143 hasConcept C2778690821 @default.
• W2022266143 hasConcept C32470452 @default.
• W2022266143 hasConcept C40767141 @default.
• W2022266143 hasConcept C502942594 @default.
• W2022266143 hasConcept C54009773 @default.
• W2022266143 hasConcept C54355233 @default.
• W2022266143 hasConcept C55493867 @default.
• W2022266143 hasConcept C74172505 @default.
• W2022266143 hasConcept C81885089 @default.
• W2022266143 hasConcept C86803240 @default.
• W2022266143 hasConceptScore W2022266143C104317684 @default.
• W2022266143 hasConceptScore W2022266143C111599444 @default.
• W2022266143 hasConceptScore W2022266143C153911025 @default.
• W2022266143 hasConceptScore W2022266143C191732599 @default.
• W2022266143 hasConceptScore W2022266143C203014093 @default.
• W2022266143 hasConceptScore W2022266143C2522874641 @default.
• W2022266143 hasConceptScore W2022266143C2778227246 @default.
• W2022266143 hasConceptScore W2022266143C2778431562 @default.
• W2022266143 hasConceptScore W2022266143C2778690821 @default.
• W2022266143 hasConceptScore W2022266143C32470452 @default.
• W2022266143 hasConceptScore W2022266143C40767141 @default.
• W2022266143 hasConceptScore W2022266143C502942594 @default.
• W2022266143 hasConceptScore W2022266143C54009773 @default.
• W2022266143 hasConceptScore W2022266143C54355233 @default.
• W2022266143 hasConceptScore W2022266143C55493867 @default.
• W2022266143 hasConceptScore W2022266143C74172505 @default.
• W2022266143 hasConceptScore W2022266143C81885089 @default.
• W2022266143 hasConceptScore W2022266143C86803240 @default.
• W2022266143 hasIssue "4" @default.
• W2022266143 hasLocation W20222661431 @default.
• W2022266143 hasLocation W20222661432 @default.
• W2022266143 hasOpenAccess W2022266143 @default.
• W2022266143 hasPrimaryLocation W20222661431 @default.
• W2022266143 hasRelatedWork W1998860632 @default.

• next